Sudha P. Desai

Manchester, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Cediranib with weekly paclitaxel or olaparib versus weekly paclitaxel for advanced or recurrent endometrial cancer (COPELIA): a multicentre, open-label, randomised, phase 2 trial in the UK.

Cediranib with weekly paclitaxel or olaparib versus weekly paclitaxel for advanced or recurrent endometrial cancer (COPELIA): a multicentre, open-label, randomised, phase 2 trial in the UK.

Journal: EClinicalMedicine

Published: April 09, 2026

Hypoxia-associated gene signature for uterine cervical cancer.

Hypoxia-associated gene signature for uterine cervical cancer.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: March 04, 2026

Homologous recombination deficiency in unselected cases of high-grade ovarian carcinoma.

Homologous recombination deficiency in unselected cases of high-grade ovarian carcinoma.

Journal: Journal of medical genetics

Published: May 05, 2025

Germline BRCA1/2 status and chemotherapy response score in high-grade serous ovarian cancer.

Germline BRCA1/2 status and chemotherapy response score in high-grade serous ovarian cancer.

Journal: British journal of cancer

Published: May 26, 2024

Real-World Concordance between Germline and Tumour BRCA1/2 Status in Epithelial Ovarian Cancer.

Real-World Concordance between Germline and Tumour BRCA1/2 Status in Epithelial Ovarian Cancer.

Journal: Cancers

Published: November 24, 2023

Exploiting a living biobank to delineate mechanisms underlying disease-specific chromosome instability.

Exploiting a living biobank to delineate mechanisms underlying disease-specific chromosome instability.

Journal: Chromosome research : an international journal on the molecular, supramolecular and evolutionary aspects of chromosome biology

Published: April 25, 2023

Predicting the likelihood of a BRCA1/2 pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancer.

Predicting the likelihood of a BRCA1/2 pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancer.

Journal: Journal of clinical pathology

Published: May 02, 2022

Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models.

Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models.

Journal: Journal of experimental & clinical cancer research : CR

Published: August 17, 2021

Extrauterine Mesonephric-like Neoplasms: Expanding the Morphologic Spectrum.

Extrauterine Mesonephric-like Neoplasms: Expanding the Morphologic Spectrum.

Journal: The American journal of surgical pathology

Published: June 29, 2021

Distinct transcriptional programs stratify ovarian cancer cell lines into the five major histological subtypes.

Distinct transcriptional programs stratify ovarian cancer cell lines into the five major histological subtypes.

Journal: Genome medicine

Published: January 21, 2021

A living biobank of ovarian cancer ex vivo models reveals profound mitotic heterogeneity.

A living biobank of ovarian cancer ex vivo models reveals profound mitotic heterogeneity.

Journal: Nature communications

Published: November 21, 2018

Reduction in postoperative endophthalmitis with intracameral cefuroxime.

Reduction in postoperative endophthalmitis with intracameral cefuroxime.

Journal: The Journal of hospital infection

Published: November 12, 2012

Showing 1-12 of 12

Last Updated: 09/26/2026